MedTrace Logo

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

NCT06331806 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-06-24

No results posted yet for this study

Summary

This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment

Conditions

  • Cardiomyopathy Due to Drug

Interventions

DIAGNOSTIC_TEST

Evaluation of myocardial fibrosis

echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Daniela Cardinale, MD · European Institute of Oncology

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-22
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06331806 on ClinicalTrials.gov